Name: Quantitative Immunohistochemistry of the Cellular Microenvironment in Patient Glioblastoma Resections (Video) | JoVE Journal
Uploaded: 2017-07-31T15:00:00.000+00:00
Duration: 5 min 45 s
Description: Learn quantitative immunohistochemistry to analyze the cellular microenvironment in patient glioblastoma resections using chromogenic staining and ImageJ. This method enables researchers to determine physiologically relevant cell ratios.

ai_agent_IP

ai_agent

maintenance

instantTrialDurationMinutes

isBiopharma

enableNewMyJoveSectionDesign

educationFeatures

seoMetaApi

ai_copilot_institution_blacklist

ai_chat_institution_blacklist

freeAccessWindow

ssoRoleCapture

scheduledMaintenanceBanner

joveLabsFeatures

disable_autoplay_for_bots

extended_trial_duration

5 minutes

The authors thank Drs. Fahad Bafakih and Jim Mandell for acquisition and identification of patient samples, Garrett F. Beeghly for assistance with immunohistochemistry, and the Biorepository and Tissue Research Facility, the Cardiovascular Research Center Histology Core, and the Biomolecular Analysis Facility at the University of Virginia for assistance with sample acquisition, immunohistochemistry, and imaging.

This protocol identifies cellular components in formalin-fixed paraffin embedded (FFPE) samples, as is typical for banked clinical patient samples. Paraffin embedding allows for the best maintenance of cellular and tissue morphology as well as has better longevity of sections. The samples used for this analysis were accessed through the University of Virginia Biorepository and Tissue Research Facility. Patient samples were selected by a neuropathologist based on a definitive diagnosis of glioblastoma (astrocytoma, WHO grade IV) who had completed tumor resections at the University of Virginia between 2010 and 2013, and were de-identified prior to this analysis11.
1. FFPE Sample Deparaffinization and Rehydration
NOTE: This portion of the protocol is specific to FFPE samples. While paraffin-embedded samples can be more useful for this analysis because of the preservation of cellular and tissue morphology, this analysis can also be done with frozen sections. If using frozen sections, this portion can be omitted and proceed directly to chromogenic immunohistochemistry.
<ol>
	<li>Perform the following washes for 5 min each: Xylene, Xylene, 100% Ethanol, 100% Ethanol, 95% Ethanol, 95% Ethanol, 70% Ethanol, Deionized water, Deionized water</li>
</ol>
2. Antigen Retrieval
NOTE: This portion of the protocol is necessary to break methylene bridges formed during formalin fixation of FFPE samples and expose antigen sites for antibodies to bind.
<ol>
	<li>Dilute Tris-based high pH antigen unmasking solution at manufacturer recommendation in distilled water.</li>
	<li>Perform heat-mediated antigen retrieval using a microwave. Other forms of heat-mediated retrieval (such as pressure cooker, vegetable steamer, or boiling water) would also suffice.
	<ol>
		<li>Add the diluted unmasking solution into a non-sealed microwaveable vessel. Place slides into vessel. Place slides into microwave.</li>
		<li>Boil for 20 min at high power. Monitor liquid levels for evaporation, and replenish with distilled water as necessary.</li>
	</ol>
	</li>
	<li>Allow samples to cool in solution for 1 h at room temperature.</li>
</ol>
3. Chromogenic Immunohistochemistry
<ol>
	<li>Outline tissue sample with a hydrophobic pen to minimize volume of reagents necessary to cover sample. 
	NOTE: Be sure to keep tissue samples hydrated and do not let them dry out as this will affect staining efficacy.</li>
	<li>Pipet enough permeabilization solution (Tris-buffered saline (TBS) + 0.01% Triton-X) to cover tissue sample (typically about 100 - 200 &#181;L).</li>
	<li>Remove and discard solution and repeat step 3.2.</li>
	<li>Incubate samples at room temperature with blocking solution (2.5% horse serum + permeabilization solution).</li>
	<li>Incubate samples overnight in 4 &#186;C with primary antibodies diluted in blocking solution. 
	NOTE: All primary antibodies used here are diluted at 1:200, but optimal dilutions can be determined using serial dilutions starting with manufacturer recommendation. Detailed information on antibodies used in this protocol was previously published11.</li>
	<li>Detect primary antibodies using a horseradish peroxidase polymer reagent corresponding with the primary antibody host animal, following manufacturer protocol.</li>
	<li>Pipet enough permeabilization solution to cover tissue sample and incubate for 5 min.</li>
	<li>Remove and discard solution and repeat Step 3.7.</li>
	<li>Incubate slides in 0.3% H2O2 in 1x TBS for 15 min.</li>
	<li>Develop samples with a peroxidase diaminobenzidine (DAB) substrate for 2 - 10 min until desired stain intensity is achieved.</li>
	<li>Counterstain samples to identify cell nuclei, such as with hematoxylin, following manufacturer protocol.</li>
	<li>Dehydrate samples with 100% ethanol and xylene.</li>
	<li>Mount samples permanently with mounting media.</li>
</ol>
4. Regions of Interest Identification
<ol>
	<li>Image slides under brightfield microscopy capable of high resolution images. 
	NOTE: Use imaging cellular components at a minimum of 20x resolution.</li>
	<li>Move camera to specific regions of interest throughout tissue samples.</li>
	<li>Save images as TIFF files for quantification.</li>
</ol>
5. Image Analysis
<ol>
	<li>Open images in ImageJ for quantification of percent coverage.</li>
	<li>Use the Threshold Colour plugin to remove purple color from hematoxylin stained nuclei.</li>
	<li>Convert image to 8-bit.</li>
	<li>Add threshold without dark background.</li>
	<li>Process image using one of the 17 pre-loaded ImageJ threshold filters (i.e. MaxEntropy) so only DAB stained portions are included in the threshold. 
	NOTE: Select the optimal pre-loaded threshold filter that minimizes inclusion of background staining. This can depend on the quality of staining and specificity of antibody. Use the same threshold for all technical replicates within each patient sample.</li>
	<li>Apply threshold.</li>
	<li>Measure percent area of thresholded image.</li>
	<li>Average percent area coverage for multiple regions within each sample.</li>
</ol>

<ol><li>Claes, A., Idema, A. J., Wesseling, P. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Diffuse+glioma+growth%3A+a+guerilla+war%5BTitle%5D)+AND+%22Acta+Neuropathol%22%5BJournal%5D)">Diffuse glioma growth: a guerilla war.</a> Acta Neuropathol. 114 (5), 443-458 (2007).</li>
<li>Holland, E. C. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Glioblastoma+multiforme%3A+the+terminator%5BTitle%5D)+AND+%22Proc.+Natl.+Acad.+Sci.+U.+S.+A%22%5BJournal%5D)">Glioblastoma multiforme: the terminator.</a> Proc. Natl. Acad. Sci. U. S. A. 97 (12), 6242-6244 (2000).</li>
<li>Wild-Bode, C., Weller, M., Rimner, A., Dichgans, J., Wick, W. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Sublethal+Irradiation+Promotes+Migration+and+Invasiveness+of+Glioma+Cells%5BTitle%5D)+AND+%22Cancer+Res%22%5BJournal%5D)">Sublethal Irradiation Promotes Migration and Invasiveness of Glioma Cells.</a> Cancer Res. 61 (6), (2001).</li>
<li>Tuettenberg, J., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Recurrence+pattern+in+glioblastoma+multiforme+patients+treated+with+anti-angiogenic+chemotherapy%5BTitle%5D)+AND+%22J.+Cancer+Res.+Clin.+Oncol%22%5BJournal%5D)">Recurrence pattern in glioblastoma multiforme patients treated with anti-angiogenic chemotherapy.</a> J. Cancer Res. Clin. Oncol. 135 (9), 1239-1244 (2009).</li>
<li>Munson, J. M., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Anti-invasive+adjuvant+therapy+with+imipramine+blue+enhances+chemotherapeutic+efficacy+against+glioma%5BTitle%5D)+AND+%22Sci.+Transl.+Med%22%5BJournal%5D)">Anti-invasive adjuvant therapy with imipramine blue enhances chemotherapeutic efficacy against glioma.</a> Sci. Transl. Med. 4 (127), 127ra36(2012).</li>
<li>Correia, A. L., Bissell, M. J. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((The+tumor+microenvironment+is+a+dominant+force+in+multidrug+resistance%5BTitle%5D)+AND+%22Drug+Resist.+Updat%22%5BJournal%5D)">The tumor microenvironment is a dominant force in multidrug resistance.</a> Drug Resist. Updat. 15 (1-2), 39-49 (2012).</li>
<li>Rubin, J. B. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Only+in+congenial+soil%3A+the+microenvironment+in+brain+tumorigenesis%5BTitle%5D)+AND+%22Brain+Pathol%22%5BJournal%5D)">Only in congenial soil: the microenvironment in brain tumorigenesis.</a> Brain Pathol. 19 (1), 144-149 (2009).</li>
<li>Bettinger, I., Thanos, S., Paulus, W. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Microglia+promote+glioma+migration%5BTitle%5D)+AND+%22Acta+Neuropathol%22%5BJournal%5D)">Microglia promote glioma migration.</a> Acta Neuropathol. 103 (4), 351-355 (2002).</li>
<li>Le, D. M., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Exploitation+of+astrocytes+by+glioma+cells+to+facilitate+invasiveness%3A+a+mechanism+involving+matrix+metalloproteinase-2+and+the+urokinase-type+plasminogen+activator-plasmin+cascade%5BTitle%5D)+AND+%22J.+Neurosci%22%5BJournal%5D)">Exploitation of astrocytes by glioma cells to facilitate invasiveness: a mechanism involving matrix metalloproteinase-2 and the urokinase-type plasminogen activator-plasmin cascade.</a> J. Neurosci. 23 (10), 4034-4043 (2003).</li>
<li>Ye, X., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Tumor-associated+microglia%2Fmacrophages+enhance+the+invasion+of+glioma+stem-like+cells+via+TGF-%CE%B21+signaling+pathway%5BTitle%5D)+AND+%22J.+Immunol%22%5BJournal%5D)">Tumor-associated microglia/macrophages enhance the invasion of glioma stem-like cells via TGF-β1 signaling pathway.</a> J. Immunol. 189, 444-453 (2012).</li>
<li>Yuan, J. X., Bafakih, F. F., Mandell, J. W., Horton, B. J., Munson, J. M. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Quantitative+Analysis+of+the+Cellular+Microenvironment+of+Glioblastoma+to+Develop+Predictive+Statistical+Models+of+Overall+Survival%5BTitle%5D)+AND+%22J.+Neuropathol.+Exp.+Neurol%22%5BJournal%5D)">Quantitative Analysis of the Cellular Microenvironment of Glioblastoma to Develop Predictive Statistical Models of Overall Survival.</a> J. Neuropathol. Exp. Neurol. , (2016).</li>
<li>Yuan, Y., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Quantitative+Image+Analysis+of+Cellular+Heterogeneity+in+Breast+Tumors+Complements+Genomic+Profiling%5BTitle%5D)+AND+%22Sci.+Transl.+Med%22%5BJournal%5D)">Quantitative Image Analysis of Cellular Heterogeneity in Breast Tumors Complements Genomic Profiling.</a> Sci. Transl. Med. 4 (157), (2012).</li>
<li>Yi, E. S., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Distribution+of+Obstructive+Intimal+Lesions+and+Their+Cellular+Phenotypes+in+Chronic+Pulmonary+Hypertension%5BTitle%5D)+AND+%22Am.+J.+Respir.+Crit.+Care+Med%22%5BJournal%5D)">Distribution of Obstructive Intimal Lesions and Their Cellular Phenotypes in Chronic Pulmonary Hypertension.</a> Am. J. Respir. Crit. Care Med. 162 (4), 1577-1586 (2000).</li>
<li>Turcan, S., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((IDH1+mutation+is+sufficient+to+establish+the+glioma+hypermethylator+phenotype%5BTitle%5D)+AND+%22Nature%22%5BJournal%5D)">IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype.</a> Nature. 483 (7390), 479-483 (2012).</li>
<li>Songtao, Q., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((IDH+mutations+predict+longer+survival+and+response+to+temozolomide+in+secondary+glioblastoma%5BTitle%5D)+AND+%22Cancer+Sci%22%5BJournal%5D)">IDH mutations predict longer survival and response to temozolomide in secondary glioblastoma.</a> Cancer Sci. 103 (2), 269-273 (2012).</li>
<li>Shinojima, N., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Prognostic+Value+of+Epidermal+Growth+Factor+Receptor+in+Patients+with+Glioblastoma+Multiforme%5BTitle%5D)+AND+%22Cancer+Res%22%5BJournal%5D)">Prognostic Value of Epidermal Growth Factor Receptor in Patients with Glioblastoma Multiforme.</a> Cancer Res. 63, 6962-6970 (2003).</li>
<li>Karpel-Massler, G., Schmidt, U., Unterberg, A., Halatsch, M. E. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Therapeutic+inhibition+of+the+epidermal+growth+factor+receptor+in+high-grade+gliomas%3A+where+do+we+stand%3F%5BTitle%5D)+AND+%22Mol.+Cancer+Res%22%5BJournal%5D)">Therapeutic inhibition of the epidermal growth factor receptor in high-grade gliomas: where do we stand?</a> Mol. Cancer Res. 7 (7), 1000-1012 (2009).</li>
<li>Badie, B., Schartner, J. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Role+of+microglia+in+glioma+biology%5BTitle%5D)+AND+%22Microsc.+Res.+Tech%22%5BJournal%5D)">Role of microglia in glioma biology.</a> Microsc. Res. Tech. 54 (2), 106-113 (2001).</li>
<li>Watters, J. J., Schartner, J. M., Badie, B. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Microglia+function+in+brain+tumors%5BTitle%5D)+AND+%22J.+Neurosci.+Res%22%5BJournal%5D)">Microglia function in brain tumors.</a> J. Neurosci. Res. 81 (3), 447-455 (2005).</li>
<li>Alves, T. R., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Glioblastoma+cells%3A+A+heterogeneous+and+fatal+tumor+interacting+with+the+parenchyma%5BTitle%5D)+AND+%22Life+Sci%22%5BJournal%5D)">Glioblastoma cells: A heterogeneous and fatal tumor interacting with the parenchyma.</a> Life Sci. 89 (15), 532-539 (2011).</li>
<li>Hambardzumyan, D., Gutmann, D. H., Kettenmann, H. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((The+role+of+microglia+and+macrophages+in+glioma+maintenance+and+progression%5BTitle%5D)+AND+%22Nat.+Neurosci%22%5BJournal%5D)">The role of microglia and macrophages in glioma maintenance and progression.</a> Nat. Neurosci. 19 (1), 20-27 (2015).</li>
<li>Zhai, H., Heppner, F. L., Tsirka, S. E. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Microglia%2Fmacrophages+promote+glioma+progression%5BTitle%5D)+AND+%22Glia%22%5BJournal%5D)">Microglia/macrophages promote glioma progression.</a> Glia. 59 (3), 472-485 (2011).</li>
<li>Placone, A. L., Quiñones-Hinojosa, A., Searson, P. C. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((The+role+of+astrocytes+in+the+progression+of+brain+cancer%3A+complicating+the+picture+of+the+tumor+microenvironment%5BTitle%5D)+AND+%22Tumor+Biol%22%5BJournal%5D)">The role of astrocytes in the progression of brain cancer: complicating the picture of the tumor microenvironment.</a> Tumor Biol. 37 (1), 61-69 (2016).</li>
<li>Rath, B. H., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Astrocytes+Enhance+the+Invasion+Potential+of+Glioblastoma+Stem-Like+Cells%5BTitle%5D)+AND+%22PLoS+One%22%5BJournal%5D)">Astrocytes Enhance the Invasion Potential of Glioblastoma Stem-Like Cells.</a> PLoS One. 8 (1), e54752(2013).</li>
</ol>

Our method proposed here is a quantitative approach to analyzing histological samples stained using traditional chromogenic immunohistochemistry. Current methodology for this type of analysis includes similar staining protocols followed by grading by independent pathologists. This method has been reliable, yet for a number of applications, a more precise understanding of the cellular make-up is required, such as better understanding of the heterogeneity associated with tumors and accurate recapitulation of tumors for in ...

Glioblastoma (GBM), the most common and malignant brain cancer, is characterized by highly diffuse invasion from the primary tumor bulk into the surrounding healthy brain parenchyma1,2. This diffuse invasion makes the tumor particularly difficult to resect fully, and the invading cancer cells that remain post-therapy is the most common reason for inevitable recurrence2,3,4. Previously, we found inhibiting the diffuse glioma cell invasion to be therapeutically beneficial5, however little is known about the complex mechanisms contributing to GBM invasion. The tumor microenvironment, or tissue surrounding the cancer, has been implicated in the progression of tumors in multiple cancers6,7. The glioblastoma tumor microenvironment, in particular, is relatively under-characterized and is uniquely complex, composing of multiple glial cells, such as astrocytes, microglia, and oligodendrocytes, as well as extracellular matrix, soluble factors, and biophysical factors. Experimentally, astrocytes and microglia have been shown to increase glioma progression and invasion8,9,10, but the composition of all glial cells in the native human brain microenvironment is unknown.
We previously showed microenvironmental components can predict patient survival by quantitatively analyzing cellular components of the glioblastoma microenvironment and incorporating our analyses into a proportional hazards model11. Here, we describe the quantitative analysis method for identifying the populations of glial cells within the tumor bulk and adjacent regions of tumor resections from glioblastoma patients. We used chromogenic immunohistochemistry to identify the glial cell populations and ImageJ to analyze percent coverage of staining for each glial population. Assessing percent coverage creates a simple measurement for determining the morphological differences of cells, particularly those affected by interactions with cancer cells. Previous studies for quantifying histopathological staining use standard staining such as hematoxylin and eosin12 or Masson&#39;s trichrome13, which do not take advantage of the specificity of antibody-based immunohistochemistry staining. Our method was developed to directly quantify the glial populations within glioblastoma patient tumor resections, which we aim to use to elucidate the complex glioblastoma microenvironment.

<table><tbody><tr><td>Xylene</td><td>Fisher Chemical</td><td>X3P</td><td></td></tr><tr><td>Ethanol</td><td></td><td></td><td></td></tr><tr><td>High pH antigen unmasking solution</td><td>Vector Labs</td><td>H-3301</td><td></td></tr><tr><td>TBS</td><td></td><td></td><td></td></tr><tr><td>Triton-X</td><td>Amresco</td><td>9002-93-1</td><td></td></tr><tr><td>Horse serum</td><td></td><td></td><td></td></tr><tr><td>Anti-ALDH1L1&amp;nbsp;</td><td>abcam&amp;nbsp;</td><td>ab56777</td><td></td></tr><tr><td>Anti-Iba1&amp;nbsp;</td><td>abcam&amp;nbsp;</td><td>ab5076</td><td></td></tr><tr><td>Anti-Oligodendrocyte Specific Protein1&amp;nbsp;</td><td>abcam&amp;nbsp;</td><td>ab53041</td><td></td></tr><tr><td>ImmPRESS anti-goat</td><td>Vector Labs</td><td>MP-7405</td><td></td></tr><tr><td>ImmPRESS Universal (anti-mouse/rabbit)</td><td>Vector Labs</td><td>MP-7500</td><td></td></tr><tr><td>Hydrogen peroxide</td><td>Sigma Aldrich</td><td>216763</td><td></td></tr><tr><td>ImmPACT DAB substrate</td><td>Vector Labs</td><td>SK-4105</td><td></td></tr><tr><td>Hematoxylin counterstain</td><td>ThermoScientific</td><td>72404</td><td></td></tr><tr><td>Histochoice Mounting Media</td><td>Amresco</td><td>H157-475</td><td></td></tr><tr><td>Aperio Scanscope</td><td>Leica Biosystems</td><td></td><td></td></tr><tr><td>Image Scanscope</td><td>Leica Biosystems</td><td></td><td></td></tr><tr><td>Super HT PAP Pen</td><td>Research Products International</td><td>195506</td><td></td></tr></tbody></table>

quantitative immunohistochemistry of the cellular microenvironment in patient glioblastoma resections

Quantitative Immunohistochemistry of the Cellular Microenvironment in Patient Glioblastoma Resections

With the growing interest in the tumor microenvironment, we set out to develop a method to specifically determine the microenvironment components within patient samples of glioblastoma, the deadliest and most invasive brain cancer. Not only are quantitative methods beneficial for accurately describing diseased tissues, they can also potentially contribute to more accurate prognosis, diagnosis, and the development of tissue-engineered systems and replacements. In glioblastoma, glial cells, such as microglia and astrocytes, have been independently correlated with poor prognosis based on pathologist grading. However, the state of these cells and other glial cell components has not been well-described quantitatively. This can be difficult due to the large processes that mark these glial cells. Furthermore, most histological analyses focus on the overall tissue sample or only within the bulk of the tumor, as opposed to delineating quantifications based on regions within the highly heterogeneous tissue. Here, we describe a method for identifying and quantitatively analyzing the populations of glial cells within the tumor bulk and adjacent regions of tumor resections from glioblastoma patients. We used chromogenic immunohistochemistry to identify the glial cell populations in patient tumor resections and ImageJ to analyze percent coverage of staining for each glial population. With these techniques we are able to better describe the glial cells throughout regions of the glioma tumor microenvironment.

For this analysis, two regions of interests within our tumor resections - the primary tumor bulk and the adjacent regions, primarily composed of healthy tissue with diffuse invading cancer cells (Figure 1A, 1B) - were identified by collaborating neuropathologists on hematoxylin and eosin stained patient samples. Within each patient sample, positive staining for astrocytes (Figure 1C), microglia (<strong class="xf...

This protocol was developed to quantitatively identify tumor microenvironment components in glioblastoma patient resections using chromogenic immunohistochemistry and ImageJ.

With the growing interest in the tumor microenvironment, we set out to develop a method to specifically determine the microenvironment components within ...

The overall goal of this protocol is to quantitively identify tumor microenvironment components in glioblastoma patient resections using chromogenic immunohistochemistry and image J.This method can help answer key questions in the tumor microenvironment field, such as how these components look in patient samples and how we can determine physiologically relevant ratios of cells. The main advantage of this technique is that it is straightforward for analysis in patient samples. The implications of this technique extend toward elucidating the undercharacterized, complex glioblastoma tumor microenvironment.Generally, individuals new to this method will struggle because timing for chromogenic development needs to be closely monitored to prevent overdevelopment and saturation of the tissue. Begin the protocol by performing the washes specified in the accompanying text protocol. Dilute tris-based high pH antigen unmasking solution and distilled water using the manufacturers recommendations.Move on to heat mediated antigen retrieval by adding the diluted unmasking solution to a non-sealed microwaveable vessel. Place slides into the vessel. Then place the vessel slides into the microwave.Next, boil the vessel for 20 minutes at high power. Monitor the liquid levels for evaporation and replenish the vessel with distilled water as necessary. Allow samples to cool in solution for one hour at room temperature.Outline the tissue sample with a hydrophobic to minimize the volume of reagents necessary to cover the sample. Then, pipe in enough permeabilization solution, 100 to 200 microliters to cover the tissue sample. Remove and discard the solution and cover the tissue sample with permeabilization solution again.Incubate the samples at room temperature with blocking solution for one hour. Then, incubate the samples overnight in four degrees Celsius with primary antibodies diluted in blocking solution. The next day, detect primary antibodies using a horseradish peroxidase polymer reagent corresponding with the primary antibody host animal.Pipe in enough permeabilization solution to cover the tissue sample and incubate the sample for five minutes. Remove and discard solution and cover the tissue sample in permeabilization solution one more time for five minutes. Incubate the slides in 0.3%hydrogen peroxide and IX TBS for 15 minutes.Develop the samples with a peroxidase diaminobenzidine or dab substrate for two to 10 minutes until the desired stain intensity is achieved. Counterstain the samples to identify cell nuclei, such as with hematoxylin following the manufacturers protocol. Dehydrate samples with 100%ethanol and xylene.Finally, mount the samples permanently with mounting media. Two regions of interest within our tumor resections, the primary tumor Bulk and the Adjacent regions, primarily composed of healthy tissue with diffused invading cancer cells were identified by collaborating neuropathologist on hematoxylin and eosin stained patient samples. Chromogenic immunohistochemistry identified positive staining for astrocytes, microglia, and oligodendrocytes within each patient sample.We performed staining with no primary antibody for a negative control. The manufacturer recommended and further dilutions before settling on the one to 200 dilution due to optimal positive staining of cell body and process with minimizing background for the anti ALDH 1l1 antibody. Using Image J, the percent coverage of OSP-1 positive oligodendrocyte staining was quantified to eventually compare differences in our regions of interest.Once the appropriate threshold has been applied to the image, the percent coverage from the threshold can be measured and compared for multiple patients. Five adjacent and bulk regions of glioblastoma or GBM patient samples, along with healthy brain tissue were compared for oligodendrocyte-specific protein one or OSP1 percent coverage. Once mastered, the staining technique can be done in four hours on the first day and two hours the second day if it is performed properly.While attempting this procedure, it's important to remember to closely monitor the tissue staining intensity and hydration.

quantitative-immunohistochemistry-cellular-microenvironment-patient

Research

JoVE Journal

Medicine

Source: Núñez, F. J., et al. Evaluation of Biomarkers in Glioma by Immunohistochemistry on Paraffin-Embedded 3D Glioma Neurosphere Cultures. J. Vis. Exp. (2019).This video demonstrates an immunohistochemical technique for labeling tumor biomarkers in paraffin-embedded brain tumor neurospheres. The neurosphere sections undergo paraffin removal and rehydration, followed by treatment to expose biomarker sites. Primary and secondary antibodies are then applied to label these biomarkers. The...

Immunohistochemical Staining of Biomarkers in Brain Tumor Neurosphere Sections

Protocol for propagation of dissociated high grade glioma surgical specimens in serum-free neurosphere medium to select for cells with cancer stem cell phenotype. For specimens that fail to grow as neurospheres, an alternative protocol is suggested. A paraffin embedding technique for maintaining the 3D neurosphere architecture for immunocytochemistry is described.

Optimization of High Grade Glioma Cell Culture from Surgical Specimens for Use in  Clinically Relevant Animal Models and 3D Immunochemistry

Presented here is a straightforward method for the isolation and flow cytometric analysis of glioma-infiltrating peripheral blood mononuclear cells that yields time-dependent quantitative data on the number and activation status of immune cells entering the early brain tumor microenvironment.

Isolation and Flow Cytometric Analysis of Glioma-infiltrating Peripheral Blood Mononuclear Cells

Here we describe a method to separate and enrich components of the tumor immune and non-immune microenvironment in established subcutaneous tumors. This technique allows for the separate analysis of tumor immune infiltrate and non-immune tumor fractions which can permit comprehensive characterization of the tumor immune microenvironment.

Enrichment and Characterization of the Tumor Immune and Non-immune Microenvironments in Established Subcutaneous Murine Tumors

Neurospheres grown as 3D cultures constitute a powerful tool to study glioma biology. Here we present a protocol to perform immunohistochemistry while maintaining the 3D structure of glioma neurospheres through paraffin embedding. This method enables the characterization of glioma neurosphere properties such as stemness and neural differentiation.

Evaluation of Biomarkers in Glioma by Immunohistochemistry on Paraffin-Embedded 3D Glioma Neurosphere Cultures

Laser microdissection (LMD) is a sensitive and highly reproducible technique that can be used to uncover pathways that mediate glioma heterogeneity and invasion. Here, we describe an optimized protocol to isolate discrete areas from glioma tissue using laser LMD followed by transcriptomic analysis.

Laser Capture Microdissection of Glioma Subregions for Spatial and Molecular Characterization of Intratumoral Heterogeneity, Oncostreams, and Invasion

Proteomic dysregulation plays an important role in the spread of diffusely infiltrating gliomas, but several relevant proteins remain unidentified. Digital spatial processing (DSP) offers an efficient, high-throughput approach for characterizing the differential expression of candidate proteins that may contribute to the invasion and migration of infiltrative gliomas.

Digital Spatial Profiling for Characterization of the Microenvironment in Adult-Type Diffusely Infiltrating Glioma

In this article, a protocol for manual tyramide signal amplification (TSA) multiplex immunofluorescence (mIF) combined with image analysis and spatial analysis is described. This protocol can be used with formalin-fixed paraffin-embedded (FFPE) sections for the staining of two to six antigens per slide depending on the slide scanner available in the laboratory.

Multiplex Immunofluorescence Combined with Spatial Image Analysis for the Clinical and Biological Assessment of the Tumor Microenvironment

We present a method for replicating the glioma tumor microenvironment at the invasive front that incorporates interstitial fluid flow. This model is a hyaluronan-collagen I hydrogel in a tissue culture insert where a fluid pressure head can be applied. Invasion can be quantified, and cells can be isolated or lysed.

A Photopolymerizable Hyaluronic Acid-Collagen Model of the Invasive Glioma Microenvironment with Interstitial Flow

This protocol successfully prepared sufficient high-quality neovascular tissue from glioma samples using laser-capture microdissection for quantitative proteomics analysis of tumor angiogenesis, overcoming the limitations of studies that traditionally focus mainly on angiogenic factors and providing a large-scale proteomics profile of glioma angiogenesis.

Preparation Of Neovascular Tissues from Human Glioma Tissues for Quantitative Proteomics Analysis of Tumor Angiogenesis

Learn quantitative immunohistochemistry to analyze the cellular microenvironment in patient glioblastoma resections using chromogenic staining and ImageJ. This method enables researchers to determine physiologically relevant cell ratios.

Quantitative Immunohistochemistry of the Cellular Microenvironment in Patient Glioblastoma Resections

Explore More Videos